International Urology and Nephrology

, Volume 48, Issue 5, pp 695–700 | Cite as

Expression and prognostic significance of ELL-associated factor 2 in human prostate cancer

  • Yachen Zang
  • Yun Dong
  • Dongrong Yang
  • Boxin Xue
  • Feng Li
  • Peng Gu
  • Haifeng Zhao
  • Shaoxiong Wang
  • Songlin Zhou
  • Rong Ying
  • Zhou Wang
  • Yuxi ShanEmail author
Urology - Original Paper



ELL-associated factor 2 (EAF2) is an androgen-regulated tumor suppressor in the prostate. The purpose of this study was to investigate the expression of EAF2 protein in human prostate cancer specimens along with BPH specimens as a control, and to evaluate potential association of EAF2 expression with clinical characteristics and overall survival of the prostate cancer patients.


The expression of EAF2 was evaluated in 44 prostate cancer and 23 BPH tissue specimens using immunohistochemistry. The relationships of EAF2 expression with clinical characteristics and overall survival rates were analyzed by Chi-square test and Kaplan–Meier method.


The immunostaining intensity of EAF2 in BPH specimens was significantly higher than that in prostate cancer (p < 0.05). EAF2 expression decreased significantly in high-grade and advanced-stage human prostate tumors and inversely correlated with PSA level, Gleason scores, bone metastasis and tumor stage. Importantly, loss of EAF2 expression was associated with a significant decrease in patient survival.


Expression of EAF2 is decreased in prostate carcinogenesis, and EAF2 loss is associated with high-risk patients and poor survival.


ELL-associated factor 2 (EAF2) Prostate cancer Overall survival Prognosis 



We would like to thank Dr. Laura Pascal for critical review and editing. This work was supported in part by NIH R01 CA186780 to Z. W., Suzhou social development fund (SYSD2013089) to Y. Z. and the Priority Academic Program Development of Jiangsu Higher Education Institutions.

Compliance with ethical standards

Conflict of interest



  1. 1.
    Wang Z, Tufts R, Haleem R, Cai X (1997) Genes regulated by androgen in the rat ventral prostate. Proc Natl Acad Sci USA 94(24):12999–13004CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Guo W, Keener AL, Jing Y et al (2015) FOXA1 modulates EAF2 regulation of AR transcriptional activity, cell proliferation, and migration in prostate cancer cells. Prostate 75(9):976–987CrossRefPubMedGoogle Scholar
  3. 3.
    Kong SE, Banks CA, Shilatifard A, Conaway JW, Conaway RC (2005) ELL-associated factors 1 and 2 are positive regulators of RNA polymerase II elongation factor ELL. Proc Natl Acad Sci USA 102(29):10094–10098CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Xiao W, Zhang Q, Jiang F, Pins M, Kozlowski JM, Wang Z (2003) Suppression of prostate tumor growth by U19, a novel testosterone-regulated apoptosis inducer. Cancer Res 63(15):4698–4704PubMedGoogle Scholar
  5. 5.
    Xiao W, Zhang Q, Habermacher G et al (2008) U19/Eaf2 knockout causes lung adenocarcinoma, B-cell lymphoma, hepatocellular carcinoma and prostatic intraepithelial neoplasia. Oncogene 27(11):1536–1544CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Pascal LE, Ai J, Rigatti LH et al (2011) EAF2 loss enhances angiogenic effects of Von Hippel-Lindau heterozygosity on the murine liver and prostate. Angiogenesis 14(3):331–343CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Xiao W, Ai J, Habermacher G et al (2009) U19/Eaf2 binds to and stabilizes von hippel-lindau protein. Cancer Res 69(6):2599–2606CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Chen Z, Liu X, Mei Z, Wang Z, Xiao W (2014) EAF2 suppresses hypoxia-induced factor 1alpha transcriptional activity by disrupting its interaction with coactivator CBP/p300. Mol Cell Biol 34(6):1085–1099CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Su F, Pascal LE, Xiao W, Wang Z (2010) Tumor suppressor U19/EAF2 regulates thrombospondin-1 expression via p53. Oncogene 29(3):421–431CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Lawler J, Detmar M (2004) Tumor progression: the effects of thrombospondin-1 and -2. Int J Biochem Cell Biol 36(6):1038–1045CrossRefPubMedGoogle Scholar
  11. 11.
    Doll JA, Reiher FK, Crawford SE, Pins MR, Campbell SC, Bouck NP (2001) Thrombospondin-1, vascular endothelial growth factor and fibroblast growth factor-2 are key functional regulators of angiogenesis in the prostate. Prostate 49(4):293–305CrossRefPubMedGoogle Scholar
  12. 12.
    Axiotis CA, Monteagudo C, Merino MJ, LaPorte N, Neumann RD (1991) Immunohistochemical detection of P-glycoprotein in endometrial adenocarcinoma. Am J Pathol 138(4):799–806PubMedPubMedCentralGoogle Scholar
  13. 13.
    Partin AW, Kattan MW, Subong EN et al (1997) Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA 277(18):1445–1451CrossRefPubMedGoogle Scholar
  14. 14.
    Ai J, Pascal LE, O’Malley KJ et al (2014) Concomitant loss of EAF2/U19 and Pten synergistically promotes prostate carcinogenesis in the mouse model. Oncogene 33(18):2286–2294CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Whang YE, Wu X, Suzuki H et al (1998) Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression. Proc Natl Acad Sci USA 95(9):5246–5250CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Yoshimoto M, Cunha IW, Coudry RA et al (2007) FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome. Br J Cancer 97(5):678–685CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Lotan TL, Gurel B, Sutcliffe S et al (2011) PTEN protein loss by immunostaining: analytic validation and prognostic indicator for a high risk surgical cohort of prostate cancer patients. Clin Cancer Res 17(20):6563–6573CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    McMenamin ME, Soung P, Perera S, Kaplan I, Loda M, Sellers WR (1999) Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage. Cancer Res 59(17):4291–4296PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2016

Authors and Affiliations

  • Yachen Zang
    • 1
  • Yun Dong
    • 2
  • Dongrong Yang
    • 1
  • Boxin Xue
    • 1
  • Feng Li
    • 3
  • Peng Gu
    • 1
  • Haifeng Zhao
    • 3
  • Shaoxiong Wang
    • 1
  • Songlin Zhou
    • 1
  • Rong Ying
    • 4
  • Zhou Wang
    • 5
    • 6
    • 7
  • Yuxi Shan
    • 1
    Email author
  1. 1.Department of UrologyThe Second Affiliated Hospital of Soochow UniversitySuzhouChina
  2. 2.Department of PathologyWuxi Hospital of Traditional Chinese MedicineWuxiChina
  3. 3.Department of PathologyThe Second Affiliated Hospital of Soochow UniversitySuzhouChina
  4. 4.Department of UrologyNanjing Medical University Affiliated Suzhou HospitalSuzhouChina
  5. 5.Department of UrologyUniversity of Pittsburgh Cancer Institute, University of Pittsburgh School of MedicinePittsburghUSA
  6. 6.Department of Molecular Pharmacology and Chemical BiologyUniversity of Pittsburgh Cancer Institute, University of Pittsburgh School of MedicinePittsburghUSA
  7. 7.Department of PathologyUniversity of Pittsburgh Cancer Institute, University of Pittsburgh School of MedicinePittsburghUSA

Personalised recommendations